Cytokinetics Launches Myqorzo Prescription Drug
Cytokinetics announced that Myqorzo is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. Myqorzo was recently approved by the U.S. Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. "With Myqorzo now available in the U.S., we are delivering on our long-standing commitment to patients living with obstructive HCM and turning the page onto a new chapter as a commercial biopharmaceutical company," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "This product launch is the culmination of decades of rigorous science, clinical development, and commercial readiness preparations, reflecting our unwavering commitment to making a meaningful difference in the lives of patients. We are grateful to the healthcare professionals, patients and advocates across the HCM community whose insights and partnerships helped bring Myqorzo to this important milestone. With our REMS program now live, and our supply chain and specialty pharmacy distribution network fully operational, we are proud to make Myqorzo available as a new treatment option for patients with oHCM."
